In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cadence grosses $86.6mm via private financing

Executive Summary

Hospital products company Cadence Pharmaceuticals grossed $86.6mm through the private sale of about 12mm common shares at $7.13 each (a 5% discount). Venrock led and was joined by Frazier Healthcare Ventures, Domain Associates, Versant Ventures, New Enterprise Associates, Bay City Capital, and T. Rowe Price Associates. The shareholders also paid $0.125 apiece for 6mm warrants, which can be exercised until February 18, 2014, and entitle the investors to buy common stock at $7.84/share.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies